Soligenix Inc. (SNGX)
2.25
-0.06 (-2.60%)
At close: Mar 03, 2025, 3:59 PM
2.31
2.63%
After-hours: Mar 03, 2025, 04:29 PM EST
No 1D chart data available
| Bid | 2.15 |
| Market Cap | 5.65M |
| Revenue (ttm) | 414.68K |
| Net Income (ttm) | -8.08M |
| EPS (ttm) | -6.43 |
| PE Ratio (ttm) | -0.35 |
| Forward PE | -0.35 |
| Analyst | n/a |
| Ask | 2.47 |
| Volume | 16,814 |
| Avg. Volume (20D) | 239,734 |
| Open | 2.32 |
| Previous Close | 2.31 |
| Day's Range | 2.18 - 2.26 |
| 52-Week Range | 1.83 - 14.88 |
| Beta | 1.83 |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 4, 1994
Employees 13
Stock Exchange NASDAQ
Ticker Symbol SNGX
Website https://www.soligenix.com
Next Earnings Release
Soligenix Inc. is scheduled to release its earnings on Mar 14, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+28.16%
Soligenix shares are trading higher following a re...
Unlock content with
Pro Subscription
7 months ago
+271%
Soligenix shares are trading higher after the company announced interim results for extended HyBryte treatment in early-stage CTCL patients.
4 months ago · prismmediawire.com
Soligenix, Inc. to Present at the 2024 ThinkEquity ConferencePrinceton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc.